IART · Integra LifeSciences Holdings Corporation

Integra LifeSciences delivered a strong first quarter in 2026, marked by revenue growth, margin expansion, and improved profitability across both GAAP and non-GAAP measures. Reported revenue of $391.9 million increased 2.4% year-over-year, with organic growth of 1.3%, reflecting resilient demand despite macroeconomic headwinds. The improvement in GAAP net loss—from $(25.3) million to $(4.6) million—and GAAP EPS from $(0.33) to $(0.06) were driven by a 460-basis-point increase in GAAP gross margin (to 55.4%), underscoring progress in supply reliability and manufacturing transition efforts, particularly the ramp-up at the Braintree facility. Adjusted metrics further highlight operational gains: adjusted EPS rose 32% YoY to $0.54, and adjusted gross margin expanded to 64.1%, supported by double-digit growth in Integra Skin and successful relaunches of PriMatrix® and Durepair®. Segment performance diverged meaningfully—Tissue Reconstruction grew 6.4% organically, while Specialty Surgery declined 0.6% organically, signaling continued strength in wound reconstruction and relative softness in instruments and ENT. Management attributed results to 'improving performance across the organization as operational rigor and improved execution take hold,' citing progress on SurgiMend® production timing and quality system remediation. The upward revision of full-year adjusted EPS guidance to $2.40–$2.50 reflects confidence in sustained momentum and the benefit of IEEPA-related tariff adjustments. With $488 million in total liquidity and a net debt position of $1.6 billion, the balance sheet remains supportive of ongoing strategic execution, including the planned fourth-quarter SurgiMend® launch and broader compliance master plan implementation.